Nicolas Sergeant

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 3

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Ronchin, FR (2010 - 2020)
Lille, FR (2017 - 2020)

Company Filing History:

10 out of 1,743

Institut National De La Sante Et De La Recherche Medicale

Université De Lille 2 Droit Et Santé

Association Institut De Myologie

patents

7. 1 out of 5,072

Centre National De La Recherche Scientifique

patents

8. 1 out of 155

Université Pierre Et Marie Curie (Paris 6)

patents

9. 1 out of 1

Universite De Lille 2 Droit Et Saute

patent

10. 1 out of 9

Centre Hospitalier Regional Et Universitaire De Lille (chru)

patents

11. 1 out of 10

UniversitÉ De Droit Et De La SantÉ De Lille 2

patents

12. 1 out of 24

Centre Hospitalier Régional Universitaire De Lille

patents

13. 1 out of 1

Universite Du Droit Et De La Santa-lille Ii

patent

where one patent can have more than one assignee

Years Active: 2010-2020

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10807958 - 1,4-bis(3-aminopropyl)piperazine derivative and its use (2020-10-20),

2. 10799556 - Treatment of myotonic dystrophy (2020-10-13),

3. 10772884 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same (2020-09-15),

4. 10537569 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same (2020-01-21),

5. 10017476 - 1,4-bis(3-aminopropyl)piperazine derivative and its use (2018-07-10),

6. 9759728 - Methods for determining human sperm quality (2017-09-12),

7. 9714245 - Carboline compounds usable in the treatment of neurodegenerative diseases (2017-07-25),

8. 9562018 - Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same (2017-02-07),

9. 9044478 - Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases (2015-06-02),

10. 8343493 - Antibodies specific of the β-amyloid peptides and their uses as diagnostic agents or drugs (2013-01-01),

11. 7723117 - Means for detecting pathological transformation of the APP protein and their uses (2010-05-25),

Title: Innovations and Contributions of Inventor Nicolas Sergeant

Introduction

Nicolas Sergeant is a prominent inventor based in Ronchin, France. He has made significant contributions to the field of medical research, particularly in the treatment of neurological disorders. With a total of 11 patents to his name, Sergeant's work has garnered attention for its potential impact on healthcare.

Latest Patents

Among his latest patents is the invention of a 1,4-bis(3-aminopropyl)piperazine derivative and its use. This invention relates to a compound that has the potential to treat and/or prevent Tauopathy, a condition associated with neurodegenerative diseases. Another notable patent focuses on the treatment of myotonic dystrophy, detailing compositions and methods aimed at alleviating this genetic disorder.

Career Highlights

Throughout his career, Nicolas Sergeant has worked with esteemed organizations such as the Institut National de la Santé et de la Recherche Médicale and Alzprotect. His work in these institutions has allowed him to advance his research and contribute to significant medical advancements.

Collaborations

Sergeant has collaborated with notable colleagues, including Luc Buee and Patricia Melnyk. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the quality of his research.

Conclusion

Nicolas Sergeant's innovative work and dedication to medical research have positioned him as a key figure in the field. His patents reflect a commitment to improving treatment options for patients with complex neurological conditions.

This text is generated by artificial intelligence and may not be accurate.